Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06401707

PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest

Brain injury is the main cause of death and disability for patients surviving cardiac arrest resuscitation and seizures are diagnosed in up to a third of these patients. The investigators are proposing a pilot randomized placebo-controlled clinical trial to evaluate the safety and feasibility of perampanel use for post-cardiac arrest status epilepticus (PCARSE) prevention after cardiac arrest.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Zuckerberg San Francisco General Hospital

San Francisco, California, 94110, United States

Location status: Recruiting

Location contact

Edilberto Amorim, MD

CONTACT

About this study

More than 500,000 Americans have a cardiac arrest every year and 100,000 survive to hospital admission. Brain injury is the main cause of death and disability for patients surviving cardiac arrest resuscitation and seizures are diagnosed in up to a third of these patients. Seizures with or without muscle jerks, i.e. myoclonic seizures, are the most common seizure type after a cardiac arrest. Despite being common, seizures are usually refractory to treatment (post-cardiac arrest refractory status epilepticus) and the vast majority of patients with this diagnosis die. We are proposing a pilot randomized placebo-controlled clinical trial to evaluate the safety and feasibility of perampanel use for PCARSE prevention after cardiac arrest. Perampanel is a non-competitive AMPA glutamate receptor antagonist approved for adjunctive treatment of partial-onset seizures and primary generalized tonic-clonic seizures, however there are no randomized trials in critically ill cardiac arrest patients at risk for seizures. This medication has been used for the management of refractory status epilepticus, including status epilepticus post-cardiac arrest. We will randomize patients to placebo or perampanel after admission to the intensive care unit. The study's primary outcome will be the incidence of severe adverse events. Secondary efficacy and safety endpoints include incidence of seizures and PCARSE, seizure frequency, time to seizure control, number of anti-seizure medications necessary for seizure control, duration of treatment with anesthetics for seizure control, and time to coma awakening. This study will help determine the safety and feasibility of primary seizure prophylaxis after cardiac arrest.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years old
  • Non-traumatic, out-of-hospital cardiac arrest
  • Comatose on admission - defined as not following commands
  • Return of spontaneous circulation (ROSC) within less than 45 minutes from the time of cardiac arrest (defined as the time of 911 or EMS (emergency medical services) witnessed arrest)
  • Admission to the intensive care unit at Zuckerberg San Francisco General Hospital

Exclusion criteria

  • Acute cerebral hemorrhage or infarction
  • Pregnancy
  • Prisoner
  • Severe kidney function impairment with creatinine clearance inferior to 30 ml/min
  • Severe liver impairment with liver function tests five times above the upper limit of normal
  • Electrographic or electroclinical seizures diagnosis using American Clinical Neurophysiology criteria confirmed by an epileptologist after cardiac arrest

Treatment and study plan

perampanel

Drug

Perampanel is a non-competitive AMPA glutamate receptor antagonist.

Other names: Fycompa

Placebo

Drug

Placebo

Primary outcomes

  1. Safety and tolerability of perampanel

    Time frame: 7 days

    percentage of participants who are able to complete the 5-day course of perampanel or placebo.

  2. Adverse and Serious Adverse Events

    Time frame: 7 days

    percentage of participants with treatment-related adverse and serious adverse events in perampanel or placebo arms.

Secondary outcomes

  1. Incidence of post-cardiac arrest refractory status epilepticus

    Time frame: 7 days

    percentage of participants with post-cardiac arrest refractory status epilepticus in perampanel or placebo arms.

  2. Incidence of post-cardiac arrest seizures

    Time frame: 7 days

    percentage of participants with post-cardiac arrest seizures in perampanel or placebo arms.

  3. Treatment intensity of post-cardiac arrest refractory status epilepticus

    Time frame: 7 days

    number of anti-seizure medications and anesthetics needed for post-cardiac arrest status epilepticus control in perampanel or placebo arms.

  4. Time to start of post-cardiac arrest refractory status epilepticus

    Time frame: 7 days

    percentage of participants with post-cardiac arrest refractory status epilepticus in perampanel or placebo arms.

  5. Neurological function at 180 days

    Time frame: 180 days

    Distribution of modified Rankin Scale (mRS) score at 180 days in perampanel or placebo arms (mRS range 0 to 6, with higher scores indicating worse outcome)

Study contacts

Contact information is provided by the study sponsor or research team.

Edilberto Amorim, MD

CONTACT

[email protected]

628-206-3203

Kevin Bao, BA

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Registry information

Acronym: PROSPER

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
May 7, 2024
Registry last updated
Jul 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.